Twitter | Pretraživanje | |
BioCentury
The leading voice for decision makers throughout the global healthcare ecosystem.
27.800
Tweetovi
876
Pratim
9.742
Osobe koje vas prate
Tweetovi
BioCentury 11 h
Gilead's O'Day on remdesivir: 'We will not get in a patent dispute'
Reply Retweet Označi sa "sviđa mi se"
BioCentury 12 h
Wednesday's management moves roundup include BioMarin's CFO stepping down, new execs for Atara and Epirium, and more
Reply Retweet Označi sa "sviđa mi se"
BioCentury 12 h
Initial efficacy data suggest CAR NK cells could compete with CAR Ts in blood cancers.
Reply Retweet Označi sa "sviđa mi se"
BioCentury 13 h
After Merck spins out slower-growing businesses to focus on innovation, the company will need recent and future deals to yield fruit in order to balance its reliance on Keytruda for growth
Reply Retweet Označi sa "sviđa mi se"
BioCentury 14 h
Trump endorses Grassley-Wyden drug pricing bill
Reply Retweet Označi sa "sviđa mi se"
BioCentury 15 h
A big win for on IPR, adding nearly $9B in market cap. With overhang lifted, investors now turn full attention to candidate
Reply Retweet Označi sa "sviđa mi se"
BioCentury 15 h
FDA's Richard Pazdur supports expanded access for unapproved uses of approved drugs
Reply Retweet Označi sa "sviđa mi se"
BioCentury 15 h
EMA hopes to lower barriers to use of real-world data in regulatory decision making by creating a centralized system for integrating RWD across Europe.
Reply Retweet Označi sa "sviđa mi se"
BioCentury proslijedio/la je tweet
Jeffrey Cranmer 5. velj
.'s Vijay Pande tells 's the firm is investing new $750M fund in “weak AI” -- speeding and scaling up tasks humans can do -- while tech that could enable “strong AI,” which does things humans can’t do, matures.
Reply Retweet Označi sa "sviđa mi se"
BioCentury proslijedio/la je tweet
Josh Berlin 21 h
Odgovor korisniku/ci @BioCentury @WHO @li_hongjiang
3/ Clinical trial delays in China could have a wide impact on the global biopharma industry. More analysis here from my colleague ->
Reply Retweet Označi sa "sviđa mi se"
BioCentury proslijedio/la je tweet
Josh Berlin 5. velj
Odgovor korisniku/ci @BioCentury @WHO
2/ICYMI: Draft report from R&D Blueprint Clinical Trials expert group singles out Gilead's remdesivir as most promising candidate for (free analysis) via
Reply Retweet Označi sa "sviđa mi se"
BioCentury proslijedio/la je tweet
Josh Berlin 4. velj
We have created a free webpage that collects analysis of the outbreak. Please bookmark this page. It will be updated frequently. The most recent story tracks clinical trials.
Reply Retweet Označi sa "sviđa mi se"
BioCentury 5. velj
Andreessen Horowitz GPs see opportunities for "weak AI," diagnostics and synthetic biology with $750M Bio Fund III
Reply Retweet Označi sa "sviđa mi se"
BioCentury proslijedio/la je tweet
Kiran Mazumdar Shaw 29. sij
BioCentury - DARPA-funded AbCellera to develop mAbs to treat coronavirus outbreak - this is what India ought to do for which we need a genomic repository of viruses ⁦
Reply Retweet Označi sa "sviđa mi se"
BioCentury proslijedio/la je tweet
Adam Gordon 4. velj
Read more analysis from in our free collection.
Reply Retweet Označi sa "sviđa mi se"
BioCentury proslijedio/la je tweet
Jeffrey Cranmer 4. velj
Delays hit clinical trials in China. 's speaks with Foundation's Dan Zhang and HitGen's Jin Li on 's impact on clinical research. For open access to all of BioCentury's coverage see:
Reply Retweet Označi sa "sviđa mi se"
BioCentury proslijedio/la je tweet
Jeffrey Cranmer 4. velj
to begin enrolling patients mid-Feb in 2 trials of to treat acute respiratory disease via 's
Reply Retweet Označi sa "sviđa mi se"
BioCentury proslijedio/la je tweet
Jeffrey Cranmer 5. velj
. draft report: 's remdesivir most "promising" candidate to treat , planning for trial under way. says its “investing pretty heavily” in manufacturing of the therapy “to make sure we’re prepared as best as we can” via
Reply Retweet Označi sa "sviđa mi se"
BioCentury proslijedio/la je tweet
Jeffrey Cranmer 5. velj
CEO O'Day: has sense of "urgency" for M&A, seeking “transformative" deals a la , as well as small- to medium-sized bolt-on takeouts. Co also working “night and day” to ramp up manufacturing for therapy via 's
Reply Retweet Označi sa "sviđa mi se"
BioCentury proslijedio/la je tweet
Jeffrey Cranmer 5. velj
At least 22 MNCs are sponsoring interventional trials in China, 18 have trial sites in Wuhan, the epicenter of the outbreak. An analysis of cos most active in the region finds Roche could be most affected. via
Reply Retweet Označi sa "sviđa mi se"